Kester Capital, the UK lower mid-market private equity specialist, has announced its investment in GXP Engaged, a leading provider of Good Clinical/Pharmacovigilance Practice (GCP/GVP) audit and related consulting services to the pharmaceutical and biotech sectors.
The multi-jurisdictional Osborne Clarke team that advised Kester on the investment was led by private equity and corporate Partners Tim Hewens (UK) and Nanni Spitzer (Germany) alongside Senior Associates Alex Littlefield (UK) and Lorenz Chwaszcza (Germany), Associates Harshna Patel (UK) and Johanna Baumann (Germany) and Trainee Solicitor Aisling Farley (UK).
Banking advice was provided by Partners Laurie Keel (UK) and Olexiy Oleshchuk (Germany) alongside Senior Associates Jon Dodds (UK). Reinhard Bunjes and Associate Irina Kharag (Germany) and Trainee Solicitor Saskia Zant-Boer (UK).
Further advice was provided by: Partner Julia Kaufmann and Senior Associate Florian Eisenmenger (IT/Data Germany), Associates Marina Fröhlich and Jonas Völkel (IP/Germany), Senior Associate Susanne Schricker (competition/Germany), Counsel Sarah Grigo and Associate Philipp Stein (Commercial/Germany).
The investment represents Kester’s sixth investment in the Life Sciences sector, and the second investment out of its latest fund, Kester Capital III. This transaction cements Kester’s reputation as one of the leading life sciences investors in the UK private equity market.
With offices in the UK, Germany and Austria, to support its global operations, GXP Engaged is a fast-growing business with an exceptional reputation for providing high-quality, third-party audit services to the biopharma market. It also provides related consulting services. The business has a proven track record of impressive growth and counts several of the largest global pharma companies as long-standing clients.
Osborne Clarke’s private equity team is a go-to practice for many companies in the pharmaceutical and life sciences sector, working with clients ranging from global businesses to fast-growth start-ups and market challengers. The team advises at every stage of company development across all corporate issues, from equity and debt fundraisings to M&A, IPOs and JVs.